Litigation Details for Supernus Pharmaceuticals, Inc v. Actavis Inc. (Fed. Cir. 2016)

Supernus Pharmaceuticals, Inc v. Actavis Inc. (Fed. Cir. 2016)

Docket		Date Filed	2016-02-23
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	7,037,525; 7,151,114; 7,722,898; 7,910,131; 8,617,600
Link to Docket	External link to docket

Biologic Drugs cited in Supernus Pharmaceuticals, Inc v. Actavis Inc.

Details for Supernus Pharmaceuticals, Inc v. Actavis Inc. (Fed. Cir. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-04	33		through dismissal (as it relates to U.S. Patent No. 8,617,600)., to terminate cross/consolidated appeal… 24 February 2016 16-1619 830 Patent Infringement (Fed. Question)	External link to document
2016-05-09	36		7,037,525 B2 5/2006 Schliitermann DERIVATIVES…’898 Patent United States Patent No. 7,722,898 ’131 patent United States Patent No. …Rudnic Patents. The Katzhendler Patent U.S. Patent No. 6,296,873 (the “Katzhendler Patent”) teaches… ‘89$ patent, the' 131 patent, and ‘600 patent, would infringe those patents; the '…infringement of U.S. Patent Nos. 7,722,898 (the “’898 patent”), 7,910,131 (the “’131 patent”), and 8,617,600	External link to document
2016-07-08	48		898 patent U.S. Patent No. 7,722,898 ’131 patent U.S. Patent No. 7,910,131 Patents-in-…prior art, the Patent Examiner identified another patent [the ’452 patent] which disclosed… Actavis’s Tablets infringe the Patents-in-Suit and that the patents are not invalid. Actavis appeals…(Appx64 (citing Appx14176)). The ’452 patent cited by the patent examiner discloses PVP in the range …Oxcarbazepine The patent specifications and the prosecution history of the ’898 patent confirm that PVP	External link to document